This clinical trial is focused on studying treatments for ovarian cancer, specifically in cases where the cancer has returned after initial treatment. The study will explore the effectiveness and safety of a treatment called sacituzumab tirumotecan, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific substances in the body. In this study, sacituzumab tirumotecan will be used alone or in combination with another medication called bevacizumab, which is also a monoclonal antibody that helps prevent the growth of blood vessels that feed tumors.

The purpose of the study is to evaluate how well these treatments work in maintaining the health of patients with platinum-sensitive recurrent ovarian cancer. This means the cancer has responded to platinum-based chemotherapy in the past but has come back. The study will compare the effects of sacituzumab tirumotecan with or without bevacizumab against the standard care, which may include observation or the use of bevacizumab. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

The study will be conducted in two parts. The first part will focus on assessing the safety and how well patients tolerate the treatment. The second part will compare the effectiveness of the treatments in preventing the cancer from getting worse. The study will last for a period of up to 84 days, during which participants will be closely monitored for any side effects and the overall impact on their health. The goal is to find out if these treatments can help improve the quality of life and extend the time patients remain free from cancer progression.